Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Working Capital to Net Assets Ratio
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. working capital to net assets ratio. Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has a Working Capital to Net Assets ratio of 31.7% as of March 2026. Working capital of CN¥791.96 Million (current assets of CN¥1.70 Billion minus current liabilities of CN¥906.46 Million) is measured against net assets of CN¥2.50 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 301096 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2025)
Working capital to net assets ratio of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2025. This chart shows how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s Working Capital to Net Assets ratio has evolved across 7 annual periods from 2019 to 2025. As of March 2026, the ratio stands at 31.7%, reflecting working capital of CN¥791.96 Million against net assets of CN¥2.50 Billion CNY. See defensive interval ratio of Hangzhou Bio-Sincerity Pharma-Tech Co.Lt to measure how many days the company can operate on defensive assets alone.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Working Capital to Net Assets Ratio by Year (2019–2025)
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. working capital to net assets ratio by year from 2019 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2025, covering 7 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Hangzhou Bio-Sincerity Pharma-Tech Co.Lt balance sheet assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 25.4% | CN¥632.17 Million | CN¥2.49 Billion | CN¥1.55 Billion | CN¥919.91 Million | ▼ -4.7 pp |
| 2024 | 30.1% | CN¥776.10 Million | CN¥2.58 Billion | CN¥1.55 Billion | CN¥769.38 Million | ▲ +1.7 pp |
| 2023 | 28.4% | CN¥761.59 Million | CN¥2.68 Billion | CN¥1.61 Billion | CN¥846.19 Million | ▼ -24.8 pp |
| 2022 | 53.1% | CN¥1.32 Billion | CN¥2.48 Billion | CN¥1.61 Billion | CN¥290.70 Million | ▼ -22.5 pp |
| 2021 | 75.6% | CN¥1.75 Billion | CN¥2.32 Billion | CN¥2.23 Billion | CN¥472.69 Million | ▲ +41.1 pp |
| 2020 | 34.5% | CN¥117.10 Million | CN¥339.54 Million | CN¥238.79 Million | CN¥121.69 Million | ▼ -22.3 pp |
| 2019 | 56.8% | CN¥158.36 Million | CN¥278.74 Million | CN¥232.66 Million | CN¥74.30 Million | — |